Name Mutation Background Effect Ref. 3xTg Injection of APPswe and tauP301L transgenes in PS1M146V knock-in mice 129/C57BL6 Intraneuronal A
at 3 months, extracellular at 6, hippocampal hyperphosphorylated tau pathology at 12 months, synaptic dysfunction [26 ] A
PPswe Carrying the mutant A
PPK670N, M671L gene Mixed background of 56.25% C57, 12.5% B6, 18.75% SJL, and 12.5% Swiss-Webster Amyloid deposition and cognitive decline starting at the age of 8 months [27 ] APOE3, APOE4 APOE knockout mice carry an inactivated APOE endogenous gene disrupted by gene targeting in embryonic stem cells. Human APOE genomic DNA fragments injected in single cell emryos fertilized by APOE knockout mice APOE knockout and C57BL6 Expression of human APOE in the brain, high cholesterol levels [28 ] APP23 cDNA of human APP with the Swedish double mutation at positions 670/671 combined with the V717I mutation, inserted to the blunt ended XhoI site of the expression cassette containing the murine Thy 1.2 gene C57BL6 A
deposition in the neocortex and hippocampus at the age of 6 months [29 ] APP715SL Swedish (KM670/671NL) and London (V717I) mutation under control of Thy1 promotor CBA/C57BL6 Amyloid plaque deposits at 6 months of age [30 ]
Human A
coding sequence knocked-in to the endogenous APP gene, combined with the Swedish (K670N/M671L) mutation 129/Sv No A
depositions, but a 9-fold increase in human A
production compared to normal human A
levels [31 ] APP/PS1 KI Double knock-in mouse:
crossed with PS1 P264L knock-in, using Cre-lox knock-in technology and endogenous promoters CD-1/129 Increase of A
42 levels, amyloid deposition and reactive gliosis by 4 months of age. [32 , 33 ] APPswe/ind Expressing human APP with Swedish mutation (K670N/M671L) and the V717I Indiana mutation under the PDGF promoter (J20 line) C57BL6
DBA/2 Increased A
production and A
deposition at 5–7 months of age, decrease in synaptophysin immunoreactivity at 2–4 months of age [34 ] APPswe/PS1
E9 Cross of APPswe and PS1
E9 (expressing human PS1 carrying the exon 9 deleted variant) C57BL6J Amyloid plaque deposition, cholinergic marker decrease, memory deficits at 6 months of age [35 ] APPswe/PS1Leu235Pro APP swedish mutation crossed with mutant human PS1 Leu235Pro C3H/HeJ/C57BL/A2G — [36 , 37 ] APPswe/PS1M146L Tg2576 combined with PS1 (M146L) mutation (under PDGF promoter) C57/B6/SJL/Swiss Webster Compared to Tg2576, 41% increase in A
42 which precedes fibrillar A
deposits in cerebral cortex and hippocampus. Reduced spontaneous alternation performance in the Y-maze. [38 ] APPV717I-C100 Expressing the C-terminal 100 amino acid of human APP with 717 London mutation C57BL6 Intracellular accumulation of soluble A
[39 ] APP-YAC The entire human APP gene inserted to the yeast artificial chromosome (YAC) B142F9, introduced to embryonic stem cell by lipofection C57BL6 Significant human APP expression in the cerebral cortex [40 ] PDAPP Indiana mutation (V717F) with portions of APP introns 6–8, driven by the PDGF promoter Extracellular A
deposits in the hippocampus from the age of 6 months and neocortex from 8 months of age [41 ] PS1-L286V Overexpressing human PS1 with L286 mutation under the control of human PDGF-
promoter FVB/N A
42 intracellular deposits at 13 months of age [42 ] TASTPM Carrying human APPswe and PS1 M146V mutations C57BL63H Cerebral A
deposition and cognitive deficits at 6 months of age [43 ] Tg19959 TgCRND8 mice plus M146L
L286V PS1 transgene in the hamster PrP gene promoter C57/C3H/129SvEv/ Tac/FVB Amyloid deposits at 1 month of age [44 ] Tg2576 Human APPswe (double K670N, M671L) inserted to hamster prion protein promoter (PrP) (is also known and referred to in the text as APPswe) C57BL6 5-fold increase in A
40 and 14 fold increase in A
42, behavioral deficits, amyloid plaques at 9 months of age [45 ] TgC100 Expressing the C-terminal 100 amino acid of human APP (with or without 717 London mutation) C57BL6 Intracellular accumulation of soluble A
[39 ] TgCRND8 Swedish and Indiana (V717F) APP mutations C57/C3H/129SvEv/ Tac/FVB Plaques at 3 months of age, increased A
42/40 ratio [46 ] TgV337M V337M longest tau, cDNA inserted to the PDGF
-chain expression vector B6SJL Hyperphosphorylated tau aggregates in the hippocampus, neurodegeneration, reduced hippocampal neural activity and behavioral abnormality [47 ]
